VIBHAVADI MEDICAL CENTER PUBLIC COMPANY LIMITEDSET: VIBHA🇹🇭 TH

MD&A · 2025

Overview of Operations

Overview of Operations

In 2025, the Company and its subsidiaries reported revenues from medical treatment of Baht 5,538.28 million (90.7% of total revenues), decreasing by Baht 191.19 million or 3.3% from the previous year. The decline was mainly attributable to a decrease in inpatient (IPD) revenue across both hospitals in Bangkok and the Northern hospital group.

Operating Results & Financial Condition

Operating Results & Profitability

Revenue

In 2025, the Company and its subsidiaries reported revenues from medical treatment of Baht 5,538.28 million (90.7% of total revenues), decreasing by Baht 191.19 million or 3.3% from the previous year. The decline was mainly attributable to a decrease in inpatient (IPD) revenue across both hospitals in Bangkok and the Northern hospital group.

(Unit : Bath Million)

Operating revenue

2025

%R

2024

%R

Change

Revenues from medical treatment

5,538.28

90.7%

5,729.46

93.1%

- 3.3%

Rental and service income

78.47

1.3%

78.20

1.3%

0.4%

Dividend income

268.84

4.4%

248.16

4.0%

8.3%

Other income

220.63

3.6%

98.44

1.6%

124.1%

Total revenues

6,106.22

100.0%

6,154.26

100.0%

- 0.8%

Dividend income

2025

2024

2023

2022

Hospital businesses

90.0%

91.2%

94.6%

90.2%

Other businesses

10.0%

8.8%

5.4%

9.8%

For dividend income, in 2025, the Company and its subsidiaries recorded dividend income of Baht 268.84 million (4.4% of total revenues), increasing by Baht 20.68 million or 8.3% from the previous year. The increase was mainly from dividends received from companies in the hospital business. During 2021–2025, approximately 90% of total dividend income was derived from hospital businesses, reflecting that most of the Company’s investments are in the healthcare sector. In addition, the Company and its subsidiaries reported other income of Baht 220.63 million (3.6% of total revenues), increasing by Baht 122.19 million or 124.1% from the previous year. This was mainly due to insurance compensation of Baht 110 million received by Lanna Hospital (CMR Group – subsidiary) following flooding in Chiang Mai in late 2024.

(Unit : Bath Million)

Operating expenses

2025

%R*

2024

%R*

Change

Cost of medical treatment

3,999.60

72.2%

4,047.15

70.6%

- 1.2%

Administrative and services expenses

927.69

16.8%

970.34

16.9%

- 4.4%

%R* = Percentage of revenues from medical treatment

In 2025, the ratio of cost of medical treatment to revenues from medical treatment was 72.2%, increasing by 1.6 percentage points from the previous year. This was mainly due to higher laboratory and X-ray costs, as well as fixed costs including depreciation of buildings and medical equipment and employee expenses following two minimum wage increases during the year.

However, the ratio of administrative and services expenses to revenues from medical treatment was 16.8%, decreasing by 0.1 percentage points from the previous year, mainly due to improved personnel cost management in the Northern hospital group, particularly in supporting functions.

(Unit:Bath Million)

Special items

2025

%R

2024

%R

Change

(Gain) loss on sale of investments in subsidiary

(1,312.92)

- 21.5%

0.41

0.0%

- 318,584.0%

(Gain) loss on sale of investments in associates

(83.24)

- 1.4%

0.00

0.0%

- 100.0%

Loss on fair value measurement of financial assets

397.19

6.5%

212.45

3.5%

87.0%

In December 2025, Chiangmai Ram Medical Business Public Company Limited (CMR) disposed of a 7.12% stake in Chiangmai Ram Hospital Co., Ltd. (CMH), reducing its shareholding from 56.37% to 49.25%, resulting in CMH’s status changing from an indirect subsidiary to an indirect associate.

Following this change, the remaining investment was remeasured at fair value, and the difference between the fair value (including consideration received) and the carrying amount of net assets of the former subsidiary was recognized as a gain on sale of investment in subsidiary of Baht 1,312.92 million (21.5% of total revenues).

In October 2025, the Company disposed of its entire investment in Thippayabadin Co., Ltd., resulting in a gain on sale of (unit:Bath Million)

Other items

2025

%R

2024

%R

Change

Finance costs

282.84

4.6%

300.46

4.9%

- 5.9%

Share of profit of associates

144.57

2.4%

55.33

0.9%

161.3%

Tax expense (income)

62.05

1.0%

89.56

1.5%

- 30.7%

Profit (loss) for the year from discontinued operations, net of tax

(109.75)

- 1.8%

293.56

4.8%

- 137.4%

In 2025, finance costs amounted to Baht 282.84 million, decreasing by Baht 17.62 million or 5.9%, mainly due to four policy rate cuts by the Bank of Thailand, reducing the policy rate from 2.25% to 1.25% by the end of the year.

(unit:Bath Million)

Share of profit of associates

2025

%

2024

%

Change

Vibharam Hospital Group

126.70

87.6%

61.86

111.8%

104.8%

Other companies

17.87

12.4%

(6.53)

- 11.8%

373.6%

Total

144.57

100.0%

55.33

100.0%

161.3%

The Company and its subsidiaries recorded a share of profit of associates of Baht 144.57 million, increasing by Baht 89.24 million or 161.3% from the previous year. Of this, 87.6% was contributed by the Vibhavadi Hospital Group, which serves middle- to high-income patients as well as patients under government welfare schemes (Social Security Scheme and NHSO).

The revenue of the Vibharam Hospital Group increased significantly due to the expansion of co-benefits services (insurance combined with social security) and the absence of reductions in reimbursement rates for high-cost inpatient cases (AdjRW > 2) by the Social Security Office during 2025.

(unit:Bath Million)

Tax expense (income) as presented on Profit and Loss

2025

2024

Change

Profit before income tax expenses – continuing operations

1,984.96

635.09

212.5%

Tax expense from continuing operations

148.76

137.10

8.5%

Deferred income tax

(86.71)

(47.54)

82.4%

Income tax for the year

62.05

89.56

- 30.7%

Tax expense (income) presented in the statement of profit or loss for 2025 amounted to Baht 62.05 million, decreasing by Baht 27.51 million or 30.7% from the previous year, comprising the following components:

  1. Current income tax

The Company and its subsidiaries recorded current income tax expense from continuing operations of Baht 148.76 million, increasing by Baht 11.66 million or 8.5% from the previous year. This increase was lower than the increase in profit before tax (from continuing operations), which rose by 212.5%, due to several special items in 2025 that were exempt from or not subject to taxation under the Revenue Code, such as gains on sale of investments in subsidiaries and associates.

  1. Deferred income tax

Deferred tax income increased by Baht 39.17 million or 82.4%, mainly due to an increase in unrealized losses from fair value measurement of financial assets.

(unit:Bath Million)

Results of Discontinued Operations

2025

2024

Change

Total revenues

2,489.73

2,843.64

- 12.4%

Total expenses

2,236.16

2,441.28

- 8.4%

Profit from operating activities

253.57

402.35

- 37.0%

Finance costs

36.44

44.16

- 17.5%

Share of profit of associates

3.79

10.57

- 64.1%

Tax expense

330.67

75.20

339.7%

Profit (loss) for the year

(109.75)

293.56

- 137.4%

Other comprehensive income (expense)

(92.13)

(909.03)

- 89.9%

Total comprehensive income (expense) for the year

(201.88)

(615.47)

- 67.2%

From the above table, the discontinued operations reported a net loss of Baht 109.75 million. The main reason was income tax expense of Baht 330.67 million, which increased by Baht 255.47 million or 339.7% from the previous year

This was mainly because, in 2025, Chiangmai Ram Hospital Co., Ltd. disposed of all its investments in ordinary shares of Ramkhamhaeng Hospital Public Company Limited (RAM). Such investments had previously been classified as financial assets measured at fair value through other comprehensive income (FVOCI). Gains from the disposal were recognized in other comprehensive income, while the related income tax was recognized in profit or loss for the year

(unit:Bath Million)

Profitability Analysis

2025

2024

Change

EBITDA*

2,884.99

1,576.30

83.0%

EBITDA Margin

47.2%

25.6%

Adjusted EBITDA*

1,488.83

1,576.30

Adjusted EBITDA Margin

24.4%

25.6%

Net profit for the year – attributable to owners of the company

1,694.90

698.61

142.6%

Net profit margin

27.8%

11.4%

Earnings per share (Baht/share)

0.1257

0.0517

143.1%

Weighted average number of ordinary shares (million shares)

13,484.70

13,522.58

The Company and its subsidiaries reported Adjusted EBITDA of Baht 1,488.83 million, with an Adjusted EBITDA margin of 24.4%, slightly decreasing compared to 25.6% in 2024

Net profit for the year amounted to Baht 1,694.90 million, increasing by Baht 996.29 million or 142.6% from the previous year, resulting in an increase in net profit margin to 27.8% from 11.4% in 2024.

Liquidity & Capital Adequacy

Liquidity and Capital Management

(Unit: Baht million)

Cash Flow

2025

Net cash provided by operating activities

1,405.31

Net cash provided by investing activities

1,072.25

Net cash used in financing activities

(2,265.83)

Net increase in cash and cash equivalents – continuing operations

211.73

Net increase in cash and cash equivalents – discontinued operations

236.24

Cash and cash equivalents, at the beginning of the year

373.77

Cash and cash equivalents, at the ending of the year

821.74

For the year ended 31 December 2025, the Company and its subsidiaries reported a net increase in cash and cash equivalents from continuing operations of Baht 211.73 million and from discontinued operations of Baht 236.24 million. Cash and cash equivalents at the beginning of the year were Baht 373.77 million, resulting in cash and cash equivalents at the end of the year of Baht 821.74 million. Details of cash flows are as follows:

For continuing operations:

Net cash provided by operating activities amounted to Baht 1,405.31 million, mainly from profit for the year.

Net cash provided by investing activities amounted to Baht 1,072.25 million, mainly from proceeds from sales of equity instruments of Baht 1,501.60 million and dividend income of Baht 360.65 million, net with capital expenditures of Baht 921.92 million.

Net cash used in financing activities amounted to Baht 2,265.83 million, mainly from dividend payments of Baht 1,365.07 million and net repayments of short-term and long-term loans from financial institutions of Baht 735.57 million.

For cash and cash equivalents from discontinued operations of Baht 236.24 million, this comprised (1) net cash provided by operating activities of Baht 757.09 million, mainly derived from profit for the year 2025; (2) net cash provided by investing activities of Baht 813.72 million, primarily from proceeds from sales of equity investments, net with cash payments for the construction of Chiangmai Ram Hospital 2; and (3) net cash used in financing activities of Baht 1,334.57 million, mainly from dividend payments.

Key Financial Ratios

2025

2024

Return Ratios (%)

Return on assets

9.49

5.00

Return on equity

14.71

5.75

Liquidity Ratios (times)

Current ratio

0.44

0.38

Asset and Liability Management (days)

Cash conversion cycle

3.04

5.32

Average inventory days

14.74

11.70

Average collection period

22.92

18.53

Average payment period

34.62

24.90

Debt Analysis (times)

Interest coverage ratio

8.02

3.91

Current portion of liabilities to Total liabilities (%)

61.44

64.25

Bank borrowings to Total liabilities (%)

71.81

69.57

Debt-to-Equity Analysis (times)

Total liabilities to equity

0.74

0.83

Interest-bearing debt to equity

0.60

0.64

Net debt to equity

0.53

0.61

Analysis of Return Ratio

The return ratios, including return on assets (ROA) and return on equity (ROE), in 2025 increased compared to 2024. This was mainly due to changes in the Group’s asset structure, namely: (1) gains from disposal of investments in subsidiaries, and (2) a decrease in average assets and average equity in the consolidated financial statements, resulting in the assets, liabilities, and equity of Chiangmai Ram Hospital Co., Ltd. (CMH) no longer being included in the Group’s consolidated financial statements.

The liquidity ratio for 2025 was 0.44 times, increasing by 15.8% from the previous year.

Analysis of Working Capital Management

The Company and its subsidiaries maintained good operational liquidity, as reflected by an improved cash conversion cycle.

The average inventory days in 2025 was 14.74 days, increasing from the previous year. Inventories mainly consist of medicines and medical supplies. The Company and its subsidiaries manage inventories under appropriate internal control systems.

The average collection period in 2025 was 22.92 days, increasing from the previous year. The Company and its subsidiaries have established credit policies and determine credit limits based on the appropriateness of counterparties, with an average credit term of approximately 30 days. Credit limits are reviewed at least annually to manage collection risk.

The average payment period in 2025 was 34.62 days, increasing from the previous year.

Analysis of Debt Ratio

The debt ratio analysis for 2025 indicates that the Company and its subsidiaries had an interest coverage ratio of 8.02 times, representing an increase of more than twofold from the previous year, reflecting an improved ability to service interest obligations. Meanwhile, the proportion of current liabilities to total liabilities was 61.44%, slightly decreasing from the previous year, indicating a reduction in short-term debt burden.

Analysis of Debt-to-Equity Ratio

The debt-to-equity ratio analysis for 2025 shows that the Company and its subsidiaries improved their capital structure compared to the previous year. The total liabilities to equity ratio was 0.74 times (decreased by 10.8%), the interest-bearing debt to equity ratio was 0.60 times (decreased by 6.9%), and the net debt to equity ratio was 0.53 times (decreased by 13.6%), reflecting a reduction in the overall debt burden.

Asset Management Capability

Financial Position

(Unit: Baht million)

Assets

2025

%

2024

%

Change

Cash and cash equivalents

821.74

3.8%

373.77

1.4%

119.9%

Trade and other receivables

297.60

1.4%

420.82

1.6%

- 29.3%

Accrued revenues from hospital operations

288.09

1.3%

380.84

1.5%

- 24.4%

Other current financial assets

833.67

3.8%

1,255.56

4.8%

- 33.6%

Other non-current financial assets

6,964.18

32.1%

10,351.69

39.7%

- 32.7%

Investments in associates

6,346.68

29.3%

3,096.87

11.9%

104.9%

Investment property

314.91

1.5%

396.02

1.5%

- 20.5%

Property, plant and equipment

4,966.44

22.9%

8,290.14

31.8%

- 40.1%

Right-of-use assets

206.90

1.0%

226.45

0.9%

- 8.6%

Goodwill

324.84

1.5%

724.89

2.8%

- 55.2%

Other assets

313.23

1.4%

584.35

2.2%

- 46.4%

Total assets

21,678.27

100.0%

26,101.41

100.0%

- 16.9%

As at 31 December 2025, the Company and its subsidiaries had total assets of Baht 21,678.27 million, decreasing by 16.9% from the previous year. This was mainly due to the disposal of the investment in Chiangmai Ram Hospital Co., Ltd. (CMH) by Chiangmai Ram Medical Business Public Company Limited (CMR), resulting in CMH’s status changing from an indirect subsidiary to an indirect associate. Consequently, the assets, liabilities, and equity of CMH and its subsidiaries were deconsolidated, and the remaining investment was recognized as an investment in an associate at fair value as of the disposal date.

Goodwill amounted to Baht 324.84 million, decreasing by Baht 400.05 million from 2024. This was mainly due to the deconsolidation of Chiangmai Ram Hospital Co., Ltd. and its subsidiaries (Theppanya Business Co., Ltd., Ramkhamhaeng Chiangmai Hospital Co., Ltd., and Pawo Hospital Co., Ltd.). The remaining goodwill relates to business combinations with Chiangmai Ram Medical Business Public Company Limited and Hariphunchai Memorial Hospital Co., Ltd., for which impairment testing indicated no impairment.

Other assets of Baht 313.23 million mainly comprise (1) inventories, including medicines, medical supplies, office supplies, and consumables, totaling Baht 127.95 million; (2) short-term loans to related parties of Baht 53.00 million; and (3) long-term loans to other persons of Baht 56.63 million.

Debt Obligations & Off-Balance-Sheet Management

(Unit: Baht million)

Liabilities and Shareholders’ Equity

2025

%

2024

%

Change

Short-term loans from financial institutions

2,840.00

13.1%

4,420.79

16.9%

- 35.8%

Other short-term loans

260.00

1.2%

387.60

1.5%

- 32.9%

Trade and other payables

994.26

4.6%

1,062.24

4.1%

- 6.4%

Advance received from social security office

284.79

1.3%

380.21

1.5%

- 25.1%

Long-term loans from financial institutions*

3,767.95

17.4%

3,800.11

14.6%

- 0.8%

Other long-term loans

486.00

2.2%

434.00

1.7%

12.0%

Lease liabilities*

90.80

0.4%

108.91

0.4%

- 16.6%

Deferred tax liabilities

157.80

0.7%

845.04

3.2%

- 81.3%

Provisions for employee benefit

208.46

1.0%

280.30

1.1%

- 25.6%

Other liabilities

112.04

0.5%

97.23

0.4%

15.2%

Total liabilities

9,202.10

42.4%

11,816.43

45.3%

- 22.1%

Total equity attributable to owners of the parent

11,634.27

53.7%

11,416.60

43.7%

1.9%

Non-controlling interests

841.90

3.9%

2,868.39

11.0%

- 70.6%

Total shareholders’ equity

12,476.17

57.6%

14,284.98

54.7%

- 12.7%

*Including current portion

Total liabilities as at 31 December 2025 amounted to Baht 9,202.10 million, decreasing by 22.1% from the previous year, mainly due to reductions in short-term loans from financial institutions of Baht 1,580.79 million and deferred tax liabilities of Baht 687.24 million.

Total equity amounted to Baht 12,476.17 million, decreasing by 12.7% from 2024, mainly due to a decrease in non-controlling interests of Baht 2,026.49 million.

Debt Securities with Financial Ratio Requirements

Debt Securities with Financial Ratio Requirements Issued?

No

Factors That May Affect Financial Condition

Factors or Incidents That May Materially Affect Financial Condition

The Company operates its medical service business under economic, social, and regulatory environments that may change. Such factors may affect the Company's financial position and operating results in the future. Key factors include the demographic trend of Thailand entering an aging society, which continuously increases the demand for medical treatment services, preventive healthcare, and chronic disease treatment.

Concurrently, the private hospital business faces increasing competition in terms of quality of medical treatment, medical technology, and specialized services, as well as competition in attracting skilled medical personnel, which may affect the Company's cost levels and operational efficiency. Furthermore, changes in government policies, laws, and regulations related to the public health system, including medical treatment rights under various government projects, may impact the Company's revenue structure and business model.

The Company places importance on continuously improving the quality of medical treatment, investing in medical technology and information systems, developing the potential of medical personnel, and closely monitoring the economic situation and trends in the public health industry. This is to enhance competitiveness and support the Company's long-term sustainable growth, with the implementation of the Company's growth strategies as follows:

  1. in efficient medical technology.

    Vibhavadi Hospital, in collaboration with Healthcare Therapeutics Co., Ltd., a subsidiary of CMC Biotech Co., Ltd. Group, signed a cooperation agreement to establish the Siam Gamma Knife Therapy Center ( Siam Gamma Knife Therapy Center), the first and only neuro-radiosurgery center in Thailand using Leksell Gamma Knife technology, a global standard for treating brain and nervous system diseases without open surgery, which officially opened its clinic on June 16, 2025.

  2. Vibhavadi 2 Hospital, which is currently under construction, is progressing according to plan for the expansion of Vibhavadi 2 Hospital in Samut Songkhram Province. The hospital's target group is general patients in the Rama 2 zone. Additionally, a cancer treatment center will also be established. The construction of Vibhavadi 2 Hospital is expected to be completed by 2026.

Trends and impacts on environmental, social, and good corporate governance aspects.

The Company emphasizes sustainable business development, considering environmental, social, and good corporate governance impacts to maximize benefits for all stakeholders. Therefore, the Company has established various policies for directors, executives, employees, customers, partners, and relevant individuals or entities to adhere to and implement, such as human rights policies and guidelines, business ethics, and partner business conduct ethics. Furthermore, the Company has joined the Thai Private Sector Collective Action Against Corruption (CAC) project, having received its second certification on December 30, 2023, to ensure stable and sustainable business growth. Additionally, the Company is ready to elevate the quality of medical treatment by procuring skilled medical personnel, high-quality and modern equipment for treatment, alongside developing hospital personnel in service provision, and environmental management. The Company has also been certified by the Department of Health, Ministry of Public Health, as a hospital capable of meeting the GREEN & CLEAN Hospital Challenge standards at an "Excellent" level, confirming that Vibhavadi Hospital effectively manages its environment while reducing greenhouse gas emissions, under the motto "VIBHA GO GREEN".

In 2025, the Company was assessed to be in the SET ESG Rating 2025 sustainable stock group in "Level A" which reflects the commitment to management and consideration of environmental, social, and good corporate governance to ensure the Company's sustainable growth.

Contents